Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 | P28472 | 12/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497874 | 0.85 | GABRB3 (0.42) | GABRB3GABRA2GABRB2CYP1A2RORC | |
| SCHEMBL497962 | 0.77 | GABRB3 (0.47) | GABRB3GABRA2GABRB2CYP1A2ALDH1A1 | |
| SCHEMBL498227 | 0.73 | NR1H4 (0.47) | GABRB3GABRA2GABRB2CYP1A2ALDH1A1 | |
| SCHEMBL498171 | 0.72 | NR1H4 (0.44) | GABRB3GABRA2GABRB2CYP1A2ALDH1A1 | |
| SCHEMBL498000 | 0.71 | ALDH1A1 (0.44) | GABRB3GABRA2GABRB2ALDH1A1 | |
| SCHEMBL25044736 | 0.70 | CYP1A2 (0.42) | GABRB3GABRA2GABRB2CYP1A2ALDH1A1 | |
| SCHEMBL2772721 | 0.68 | KCNJ5 (0.39) | — | |
| SCHEMBL2771556 | 0.66 | PDE4B (0.39) | ALDH1A1NOTUM | |
| SCHEMBL2131569 | 0.65 | NOTUM (0.42) | GABRB3GABRA2GABRB2CYP1A2ALDH1A1 | |
| SCHEMBL4356417 | 0.65 | MAPK14 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | GABRB3 448/4885GABRA2 1161/4885GABRB2 473/4885 |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | GABRB3 554/4885GABRA2 1309/4885GABRB2 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.